Phaseline

Targets › CDC42

CDC42 (Cell division control protein 42 homolog): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses. (UniProt, P60953)

Open in Phaseline: the race on CDC42, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MBQ PharmaMBQ-167
Rho GTPase inhibitor (Rac and Cdc42 inhibitor)
RAC1, CDC42Phase 1Breast CancerDec 2026

Conditions

Breast Cancer (1)

Modalities

small molecule (1)

Companies

MBQ Pharma (1)

Related targets

RAC1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.